ALNY vs MDGL
ALNY: Alnylam is a pioneer in RNA interference (RNAi) therapeutics, using gene-silencing technology to treat rare genetic diseases and cardiovascular conditions. MDGL: Madrigal Pharmaceuticals is a biopharmaceutical company commercializing Rezdiffra, the first and only FDA-approved therapy for adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.
Side-by-side fundamentals
| Metric | ALNY | MDGL | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $278.40 | $551.25 | |
| Market cap as of 2026-08-03 | $37.3B | $12.7B | |
| P/E as of 2026-08-03 | 33.96 | n/a | |
| PEG as of 2026-08-03 | 0.75 | -134.35 | MDGL lower |
| Net margin as of 2026-08-03 | +16.8% | -27.3% | ALNY higher |
| Gross margin as of 2026-08-03 | +79.7% | +93.1% | MDGL higher |
| Operating margin as of 2026-08-03 | +19.9% | -27.9% | ALNY higher |
| ROE as of 2026-08-03 | +93.6% | -50.1% | ALNY higher |
| ROA as of 2026-08-03 | +15.8% | -25.4% | ALNY higher |
| Debt / equity as of 2026-08-03 | 2.02 | 0.63 | MDGL lower |
| Revenue growth (YoY) as of 2026-08-03 | +95.1% | +256.8% | MDGL higher |
| Revenue CAGR (3y) SEC XBRL | +53.0% | n/a | |
| Beta as of 2026-08-03 | 0.26 | -1.05 | |
| 1-year return as of 2026-07-27 close | -15.3% | +84.7% | MDGL higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.